ECSP003462A - CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) - Google Patents
CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K)Info
- Publication number
- ECSP003462A ECSP003462A ECSP003462A ECSP003462A EC SP003462 A ECSP003462 A EC SP003462A EC SP003462 A ECSP003462 A EC SP003462A EC SP003462 A ECSP003462 A EC SP003462A
- Authority
- EC
- Ecuador
- Prior art keywords
- ino1024k
- case
- ccr5 antagonist
- interferon alpha
- antagonist combination
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe el uso de un interferón-alfa pegilado, y el antagonista CCR5, adicionalmente en asociación con por lo menos uno de ribavirina, IL-2, IL-12, pentafusida sola o en combinación con una terapia de droga anti HIV-1, por ejemplo HAART, para la preparación de un medicamento para el tratamiento de infecciones de HIV-1 asi como también infecciones de HIV-1 como asi también co-infecciones de HIV-1 y HCV en pacientes adultos y pediátricos que no han sido sometiods a tratamiento, asi como también pacientes adultos y pedriáticos que han experimentado tratamiento.The use of a pegylated interferon-alpha, and the CCR5 antagonist, is described, additionally in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with anti-HIV-1 drug therapy, for example HAART, for the preparation of a medicine for the treatment of HIV-1 infections as well as HIV-1 infections as well as co-infections of HIV-1 and HCV in adult and pediatric patients who have not undergone treatment, as well as adult and pediatric patients who have undergone treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003462A true ECSP003462A (en) | 2000-12-19 |
Family
ID=42041089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003462A (en) |
-
2000
- 2000-05-02 EC ECSP003462 patent/ECSP003462A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023824A1 (en) | HIV THERAPY COMBINATION OF ANTAGONIST CCR5-INTERFERON ALFA PEGILADO. | |
| AR019551A1 (en) | USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C | |
| PE119199A1 (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| EA200200812A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING LOW DOSE OF ENTEKAVIR, AND ITS APPLICATION | |
| AR023541A1 (en) | HCV COMBINATION THERAPY | |
| CY1114594T1 (en) | USE OF [D-MEALA] 3 [ETVAL] 4-CYCLOSPORIN FOR TREATMENT INFECTIOUS C AND PHARMACEUTICAL COMPOSITION INCLUDING [4-D] ET-4 | |
| DK0741577T3 (en) | The use of enterferon, subtype alpha 8, in the manufacture of drugs for the treatment of viral infections in the liver | |
| BR9707154A (en) | Modulation of cytokine expression in th1 / th2 by ribavirin and ribavirin analogues in activated lymphocytes | |
| ES2058651T3 (en) | USE OF GUANIDINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICINE WITH ANTAGONIST ACTIVITY OF NPY. | |
| BR0108997A (en) | Adjuvant Immune Therapy for HIV | |
| PE20001386A1 (en) | COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA | |
| BR9915644A (en) | Use of 17-ketoesteroid compounds and their derivatives, metabolites and precursors in the treatment of hepatitis c virus and other togaviruses | |
| AR029337A1 (en) | USE OF INTERFERON ALFA PEGILADO FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THERAPY AGAINST HIV | |
| AR039915A1 (en) | TREATMENT OF HEPATITIS C IN THE ASIAN POPULATION | |
| BRPI0409711A (en) | treatment or prevention of viral respiratory infections with alpha thymosin peptides | |
| PE20010026A1 (en) | COMPOSITION INCLUDING INTERFERED ALPHA PEGILADO | |
| EP1240899A3 (en) | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | |
| DE69807129D1 (en) | Use of a combination of beta-sitosterol and beta-sitosterol glucoside for the manufacture of a medicament for the treatment of HIV infection | |
| ECSP003373A (en) | HIV THERAPY | |
| BRPI0406985A (en) | Hcv combination therapy | |
| DE3783122D1 (en) | USE OF RECOMBINED HUMAN ALPHA INTERFERON FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR TREATING THE AIDS VIRUS. | |
| BR9812466A (en) | Use of ifn-alfa and amantadine for the treatment of chronic hepatitis C | |
| BR0113115A (en) | Hepatitis C treatment with thymosin, interferon and ribavirin | |
| Scheibel | Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James | |
| BR0309375A (en) | Treatment of metabolic syndrome |